Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway

Methotrexate-bestatin interaction: Involvement of P-glycoprotein and organic anion transporters in rats

(2014) Yanna Zhu et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3

(2014) Na Zhao et al.   Molecular Cancer

MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2)

(2013) Meng-Tao Ma et al.   CANCER LETTERS

Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin

(2013) Xiaokui Huo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Dioscin Restores the Activity of the Anticancer Agent Adriamycin in Multidrug-Resistant Human Leukemia K562/Adriamycin Cells by Down-Regulating MDR1 via a Mechanism Involving NF-κB Signaling Inhibition

(2013) Lijuan Wang et al.   JOURNAL OF NATURAL PRODUCTS

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

(2012) Wen-jing Zhou et al.   BRITISH JOURNAL OF PHARMACOLOGY

H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2

(2011) Ning Wei et al.   BIOCHEMICAL PHARMACOLOGY

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

(2011) R. S. Finn et al.   CLINICAL CANCER RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo

(2010) Y. Dai et al.   BLOOD

LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast Cancer

(2010) Y.-L. Choi et al.   CANCER RESEARCH

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

(2010) Julia Salih et al.   INTERNATIONAL JOURNAL OF CANCER

Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

(2009) Amit K. Tiwari et al.   BIOCHEMICAL PHARMACOLOGY

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function

(2009) Li-yang Tao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2

(2009) Chun-ling Dai et al.   CANCER LETTERS

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

(2009) Sandra E. Ghayad et al.   INTERNATIONAL JOURNAL OF CANCER

P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib

(2009) Y. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function

(2009) Li-sheng Zheng et al.   PLoS One

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

(2008) C.-l. Dai et al.   CANCER RESEARCH